Key result
TRICENTO G2 implantation improves RV fractional area change by ~19 percentage points in severe TR.
Why the study?
Severe tricuspid regurgitation causes recurrent cardiac decompensation and right ventricular dysfunction, and some patients are ineligible for surgery or transcatheter edge-to-edge repair, necessitating novel treatment options.
Case Report (n=1)
No
The novel TRICENTO G2 transcatheter bicaval valved stent graft may offer a feasible compassionate use treatment option for patients with symptomatic severe tricuspid regurgitation who are ineligible for approved surgical or transcatheter interventions.
BACKGROUND: Tricuspid regurgitation (TR) is crucial for recurrent cardiac decompensation. Heterotopic transcatheter approaches enable symptomatic treatment of TR in patients who are ineligible for surgery or transcatheter edge-to-edge repair. The TRICENTO G2 prosthesis is a transcatheter bicaval valved stent graft, not yet approved for the market. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: To the best of our knowledge, this is the first published case of successful TRICENTO G2 transcatheter heart valve implantation, performed as compassionate use in an 81-year-old man with symptomatic TR following multiple interventions. No major complications occurred during the procedure, and a short-term functional improvement in right ventricular function resulted. Given intermittent third-degree atrioventricular block, leadless pacemaker implantation was conducted subsequently. DISCUSSION: The TRICENTO G2 represents a promising treatment option for symptomatic TR. However, wise patient selection and vigilant postprocedural observation are essential. NOVELTY: The implementation of the TRICENTO G2 may expand our interventional armamentarium for treating TR. TAKE-HOME MESSAGE: The TRICENTO G2 may improve tailored treatment of patients with symptomatic TR and right ventricular dysfunction who are ineligible for approved interventions.
No takes yet. Share an insight, caveat, or question.
Henes et al. (2026) conducted a case report in Severe tricuspid regurgitation and symptomatic right heart failure (n=1). TRICENTO G2 transcatheter bicaval valved stent graft was evaluated on Procedural success and right ventricular functional improvement. The TRICENTO G2 transcatheter heart valve was successfully implanted without major complications in a patient with severe tricuspid regurgitation, improving right ventricular fractional area change from 21% to 40%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: